BMS, AbbVie nab 'breakthrough' tag for multiple myeloma-fighting antibody

A new drug for blood cancer from Bristol-Myers Squibb ($BMY) and AbbVie ($ABBV) is on the fast track to FDA approval, winning a priority review to treat multiple myeloma. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.